Beta Bionics Faces Class Action Over Alleged Concealment of Device Risks

The legal action, spearheaded by the firm Hagens Berman, centers on allegations that Beta Bionics management downplayed regulatory scrutiny while concealing thousands of safety complaints. During the class period, executives repeatedly touted the iLet device’s ease of use and automated capabilities. When faced with an FDA Form 483 in October 2025, CEO Sean Saint characterized the inspection as routine and insisted the findings were merely administrative issues regarding complaint definitions, rather than systemic safety failures.

Evidence surfaced on February 24, 2026, when the FDA released a warning letter detailing significant violations. The agency found that the company failed to investigate or report malfunctions linked to life-threatening hypoglycemic events, violating requirements to notify regulators of incidents involving serious injury or death within 30 days. Reed Kathrein, a partner at Hagens Berman, stated the investigation focuses on whether the company prioritized revenue over patient safety. Investors seeking to participate in the litigation or whistleblowers with non-public information are encouraged to contact the firm before the November deadline.